COMMONWEALTH OF MASSACHUSETTS

SUFFOLK COUNTY		BOARD OF REGISTRATION IN PHARMACY
In the Matter of)	
CVS #23).	PHA-2022-0022
DS90049)	PHA-2022-0058

CONSENT AGREEMENT FOR PROBATION

The Massachusetts Board of Registration in Pharmacy ("Board") and CVS #23 ("Licensee" or "Pharmacy"), a pharmacy licensed by the Board, DS90049, do hereby stipulate and agree that the following information shall be entered into and become a permanent part of the Pharmacy's record maintained by the Board:

- 1. The Pharmacy acknowledges the Board opened a complaint against its pharmacy license related to the conduct set forth in Paragraph 2, identified as Docket No. PHA-2022-0022/PHA-2022-0053 ("the Complaint").
- 2. The Board and the Pharmacy acknowledge and agree to the following facts:
 - a. On or about January 5, 2022, the Pharmacy discovered a loss of #365 phenobarbital 16.2mg tablets, in violation of 247 CMR 9.01(5).
 - b. The Pharmacy was unable to determine the cause of the loss.
 - c. The Pharmacy submitted an untimely final Report of Loss of Controlled Substances (RLCS) on or about April 21, 2022, in violation of Board of Registration in Pharmacy (BORP) Policy 2018-05; Requirements and Procedures for Reporting Theft or Loss of Controlled Substances.
 - d. On or about December 17, 2021, the Pharmacy discovered a loss of #100 oxycodone-acetaninophen 10-325mg tablets, in violation of 247 CMR 9.01(5).
 - e. The Pharmacy was unable to determine the cause of the loss.
 - f. The Pharmacy submitted an untimely final BORP RLCS on or about February 16, 2022, in violation of BORP Policy 2018-05.

OVS #23 D890049 PHA:2022-0022/PHA-2022-0053

¹ The term "License" applies to both a current license and the right to renew an expired license.

- 3. The Board and Licensee acknowledge and agree the facts described in Paragraph 2 warrant disciplinary action by the Board under M.G.L. c. 112, §§ 42A & 61 and 247 CMR 10.03(1)(a) & (v).
- 4. The Pharmacy agrees that its pharmacy license shall be placed on PROBATION for One (1) Year ("Probationary Period"), commencing with the date on which the Board signs this Agreement ("Effective Date").
- 5. During the Probationary Period, the Pharmacy agrees that it shall comply, to the Board's satisfaction, with all laws and regulations governing the practice of pharmacy.
- 6. The Board agrees that in return for the Pharmacy's execution and its successful compliance with all the requirements of this Agreement, the Board will not prosecute the Complaint.
- 7. If and when the Board determines that the Pharmacy has complied to the Board's satisfaction with all the requirements contained in this Agreement, the Probationary Period will terminate One (1) Year after the Effective Date upon written notice to the Licensee from the Board.
- 8. If the Pharmacy does not materially comply with each requirement of this Agreement, or if the Board opens a Subsequent Complaint during the Probationary Period, the Pharmacy agrees to the following:
 - a. The Board may upon written notice to the Pharmacy, as warranted to protect the public health, safety, or welfare:
 - i. EXTEND the Probationary Period;
 - ii. MODIFY the Probation Agreement requirements; or
 - iii. IMMEDIATELY SUSPEND the Pharmacy's license.
 - b. If the Board suspends the Pharmacy's license pursuant to Paragraph 8 the suspension shall remain in effect until:

² The term "Subsequent Complaint" applies to a complaint opened after the Effective Date concerning acts, omissions, or events occurring after the Effective Date, which (1) alleges that the Pharmacy engaged in conduct that violates Board statutes or regulations, and (2) is substantiated by evidence, as determined following the complaint investigation during which the Pharmacy shall have an opportunity to respond.

- i. the Board provides the Pharmacy written notice that the Probationary Period is to be resumed and under what terms;
- ii. the Board and the Pharmacy sign a subsequent agreement; or
- iii. the Board issues a written final decision and order following adjudication of the allegations (1) of noncompliance with this Agreement, and/or (2) contained in the Subsequent Complaint.
- 9. The Pharmacy agrees that if the Board suspends its license in accordance with Paragraph 8, it will immediately return its current Massachusetts license to the Board, by hand or certified mail. The Pharmacy further agrees that upon said suspension, it will no longer be authorized to operate as a pharmacy in the Commonwealth of Massachusetts and shall not in any way represent itself as a pharmacy until such time as the Board reinstates license or right to renew such license.
- 10. The Pharmacy understands that it has a right to formal adjudicatory hearing concerning the Complaint and that during said adjudication it would possess the right to confront and cross-examine witnesses, to call witnesses, to present evidence, to testify on its own behalf, to contest the allegations, to present oral argument, to appeal to the courts, and all other rights as set forth in the Massachusetts Administrative Procedures Act, M.G.L. c. 30A, and the Standard Adjudicatory Rules of Practice and Procedure, 801 CMR 1.01 et seq. The Pharmacy further understands that by executing this Agreement it is knowingly and voluntarily waiving its right to a formal adjudication of the Complaints.
- 11. The Pharmacy acknowledges that it has been at all times free to seek and use legal counsel in connection with the Complaint and this Agreement.
- 12. The Pharmacy acknowledges that after the Effective Date, the Agreement constitutes a public record. The Board may forward a copy of this Agreement to other licensing boards, law enforcement entities, and other individuals or entities as required or permitted by law.
- 13. The Pharmacy understands and agrees that entering into this Agreement is a voluntary and final act and not subject to reconsideration, appeal, or judicial review.

	s Agreement certifies that he/she is authorized to behalf of the Pharmacy, and that he/she has rea	
01/03/23 sig elec. applied	Les Le	
Witness (sign and date)	Authorized Representative of Pharmacy (sign and date) 01/03/23	
·	Leo Lariviere, Dir. Regulatory Affairs (print name of Authorized Representative)	
•	David Sencabaugh	
	David Sencabaugh, R. Ph. Executive Director Board of Registration in Pharmacy	
S\\8\2023 Effective Date		

Fully Signed Agreement Sent to Licensee on 5 23 23

Certified Mail No. 7020 6090 0000 (273 130)

CVS#23 DS90049 PHA-2022-0022/PHA-2022-0058